XJPX
2934
Market cap67mUSD
Oct 09, Last price
1,980.00JPY
1D
-0.95%
1Q
20.73%
IPO
-50.75%
Name
J Frontier Co Ltd
Chart & performance
P/E
—
P/S
0.47
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.93%
Rev. gr., 5y
21.23%
Revenues
22.24b
+3.40%
Net income
-321m
L
CFO
454m
-10.74%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
J Frontier Co.,Ltd. engages in the healthcare sales, medical care sales, and healthcare marketing businesses in Japan. The company operates SOKUYAKU, a platform for online medical treatment, online medication guidance, home delivery of prescription drugs, and digital transformation support for medical institutions. The company also sells health foods, health, beauty, education, healing, medicine, and medical care products through mail order; and provides product sales promotion support services. In addition, it offers Internet advertising for medical institutions and healthcare-related companies; and web marketing, in-store and TV shopping distribution, BPO support for logistics, etc. J Frontier Co.,Ltd. was incorporated in 2008 and is based in Shibuya, Japan.
Key people
Atsuhiro Nakamura
Executive President, Representative Director · since 2021
Yuya Higuchi
Executive Officer, Chief Financial Officer, Chief Director of Business Planning, Director · since 2025
Nana Fukazawa
Executive Officer, Chief Director of SOKUYAKU Business · since 2022
Sumiko Okamoto
Executive Officer, Chief Director of Corporate · since 2023
Tomotake Hasumi
Director · since 2025
Tsutomu Akita
Independent Director · since 2025
Kazuteru Furukawa
Independent Director · since 2023
Akitoshi Imamura
Independent Director · since 2023
Headquarters & legal address
渋谷二丁目9番9号
東京都 渋谷区 150-0002
JP
東京都 渋谷区 150-0002
JP
Address
2-9-9, Shibuya
Shibuya-ku Tokyo 150-0002
JP
Shibuya-ku Tokyo 150-0002
JP
Other language
J Frontier Co., Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2026‑05 | 2025‑05 | 2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||